CA2802176A1 - Methods of mitigating effects of radiation and reducing the risk of systemic infection - Google Patents

Methods of mitigating effects of radiation and reducing the risk of systemic infection Download PDF

Info

Publication number
CA2802176A1
CA2802176A1 CA2802176A CA2802176A CA2802176A1 CA 2802176 A1 CA2802176 A1 CA 2802176A1 CA 2802176 A CA2802176 A CA 2802176A CA 2802176 A CA2802176 A CA 2802176A CA 2802176 A1 CA2802176 A1 CA 2802176A1
Authority
CA
Canada
Prior art keywords
gly
asp
ala
subject
thrombin peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2802176A
Other languages
English (en)
French (fr)
Inventor
Darrell Carney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA2802176A1 publication Critical patent/CA2802176A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
CA2802176A 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection Abandoned CA2802176A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35406710P 2010-06-11 2010-06-11
US61/354,067 2010-06-11
PCT/US2011/040006 WO2011156729A2 (en) 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection

Publications (1)

Publication Number Publication Date
CA2802176A1 true CA2802176A1 (en) 2011-12-15

Family

ID=44533067

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2802176A Abandoned CA2802176A1 (en) 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection

Country Status (5)

Country Link
EP (1) EP2579891A2 (cg-RX-API-DMAC7.html)
JP (1) JP2013529600A (cg-RX-API-DMAC7.html)
AU (1) AU2011265228A1 (cg-RX-API-DMAC7.html)
CA (1) CA2802176A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011156729A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4132948A4 (en) * 2020-04-07 2024-01-03 Chrysalis Biotherapeutics TP5088 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
WO2004005317A2 (en) 2002-07-02 2004-01-15 The Board Of Regents, The University Of Texas System Thrombin peptide derivative dimers
WO2004014937A2 (en) 2002-07-02 2004-02-19 The Board Of Regents, The University Of Texas System Thrombin peptide derivatives
US7294596B2 (en) 2005-03-14 2007-11-13 Diamorph Ceramic Ab Sintered ceramic material with improved properties and method for its manufacturing
EP2063910A2 (en) * 2006-09-22 2009-06-03 Orthologic Corp. Method of treating endothelial dysfunction
US20100330028A1 (en) * 2007-04-10 2010-12-30 The Board Of Regents The Universityof Texas System Combination therapy for chronic dermal ulcers

Also Published As

Publication number Publication date
EP2579891A2 (en) 2013-04-17
JP2013529600A (ja) 2013-07-22
WO2011156729A2 (en) 2011-12-15
WO2011156729A3 (en) 2012-05-10
AU2011265228A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
EP2875826B1 (en) Composition for preventing or treating sepsis
RU2139085C1 (ru) Средство, стимулирующее репаративные процессы, и способ его применения
ES2741476T3 (es) Método para el tratamiento o reducción de PFE
JP4307561B2 (ja) 創傷の治癒
AU2014346051B2 (en) Use of IL-22 dimers in manufacture of medicaments for treating pancreatitis
CN102482323B (zh) 新型肽及其应用
ZA200603396B (en) Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
AU7439801A (en) Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation
US20130101574A1 (en) Methods of using thrombin peptide derivatives
JPS6366128A (ja) 動物およびヒト癌の治療に用いられるｃ反応性タンパク質
CA2802176A1 (en) Methods of mitigating effects of radiation and reducing the risk of systemic infection
EP2687224A1 (en) Medicament for wound treatment
JP2008535872A (ja) 免疫障害を持つ個体の処置におけるマンナン結合レクチン（ｍｂｌ）の新規癌適用
Berlanga Heberprot-P: antecedentes experimentales y bases farmacológicas
TW201302214A (zh) 治療或預防皮膚癌之類鋅手指胜肽、其表現質體、及包含其之醫藥組成物
WO2024189056A1 (en) Annexin a1 administration regime
US8895502B2 (en) β2-glycoprotein I peptide inhibitors
US10646553B2 (en) Use of recombinant human calcineurin B subunit
CN101657465A (zh) 肽、组合物及其应用
WO2003045322A2 (en) Method for treating and preventing pancreatitis
RU2008125169A (ru) Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента грелин и его производные или вещество, воздействующее на рецептор ghs-r1а
TWI548415B (zh) 狗圍肛腺瘤之治療方法
RU2833679C1 (ru) Применение пептида Thr-Lys-Pro-Arg-Pro-Gly-Pro для защиты инсулярного аппарата поджелудочной железы и её экзокринного отдела от токсических деструктивных воздействий
CN112190687B (zh) 一种用于减少皮肤创伤瘢痕的药物及其应用
CN120939206A (zh) Metrnl蛋白与氯吡格雷联合治疗血栓的药物组合物及其应用

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20160610